Deepverge PLC Update - Proposed Financing,Proposed Board Changes (9515D)
25 October 2022 - 5:01PM
UK Regulatory
TIDMDVRG
RNS Number : 9515D
Deepverge PLC
25 October 2022
25 October 2022
DeepVerge PLC
("DeepVerge" or "Company")
Update on Proposed Financing / Proposed Board Changes
DeepVerge (AIM: DVRG), the environmental and life science group
of companies that develops and applies AI and IoT technology to
analytical instruments for the analysis and identification of
bacteria, virus and toxins, announces an update on the Proposed
Financing and details of proposed changes to the board, and to the
roles undertaken by existing directors.
Update on Proposed Financing
Further to the RNS announcement of 12 October 2022, the Board is
pleased to advise that the fundraising process, coordinated by the
Company's brokers Turner Pope, continues to progress, despite
challenging market conditions. We look forward to updating
shareholders and the market in the near term. H owever, there can
be no guarantee that sufficient equity funds can be raised, nor the
terms thereof.
Board and Management changes
The Company has doubled turnover every year from GBP0.27m in
2018 to GBP9.3m in 2021 with a forecast of GBP18m this year.
This fast pace of growth has stretched both the balance sheet
and the existing management team. As a consequence a new CEO, CFO
and Non-Executive director will be recruited.
The following Board changes are expected to take effect
immediately upon the announcement of the Proposed Financing:
Gerard Brandon will step down as Chief Executive remaining on
the board as Executive Director with responsibility for the Modern
Water Division.
Dr Nigel Burton will become interim Chief Executive while the
Company commences the search for a new Group Chief Executive.
Fionan Murray will remain on the Board as Executive Director
with responsibility for the Skin Trust Club and Labskin
Division.
Camillus Glover will leave the board but will remain as Chief
Financial Officer while the Company commences the search for a new
Group Finance Director.
A further independent non-executive director will be appointed
as soon as practicable.
For further information, please contact:
Enquiries:
DeepVerge plc Ross Andrews, Chairman +44 (0) 1904 40 4036
SPARK Advisory Partners
Limited
(Nominated Adviser) Neil Baldwin +44 (0) 113 370 8974
Turner Pope Investments
(TPI) Limited Andy Thacker/James
(Broker) Pope +44 (0) 20 3657 0050
Market Abuse Regulation (MAR) Disclosure
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFELEDLEESESS
(END) Dow Jones Newswires
October 25, 2022 02:01 ET (06:01 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Feb 2025 to Mar 2025
Integumen (LSE:SKIN)
Historical Stock Chart
From Mar 2024 to Mar 2025